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With the goal of ﬁnding serological markers to monitor patients with early- as well as late-stage melanoma, we
compared the levels of the cytoplasmic melanoma-associated antigens (CYT-MAA) and high-molecular-weight
melanoma-associated antigen (HMW-MAA) in the sera of melanoma patients and controls. Using double-sandwich
ELISA, we measured levels of both antigens in 117 patients and in 62 age- and sex-matched controls. Patients were
stratiﬁed into four risk group based on stage of the disease. Serum levels of both markers were significantly higher
in melanoma patients than in controls. CYT-MAA was the more sensitive marker, with 61% of patients showing
elevated levels regardless of the stage of disease. HMW-MAA was elevated in 29%. Elevated CYT-MAA was also
significantly correlated with poorer clinical outcome. By multivariate analysis (adjusting for stage and age), pa-
tients who had elevated CYT-MAA were 81% more likely to recur than patients with undetectable levels (hazard
ratio¼ 1.81, 95% CI¼ [1.07, 3.06], p-value¼ 0.03). Elevated levels of HMW-MAA did not correlate with poor prog-
nosis. These results suggest that both CYT-MAA and HMW-MAA are serum markers for residual melanoma in
patients with resected disease. Furthermore, CYT-MAA appears to be a prognostic marker of clinical outcome in
melanoma vaccine-treated patients.
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Measurement of tumor markers in serum is increasingly
being used in the clinical management of several malig-
nancies; the most frequently assessed are serum carcino-
embryonic antigen in colorectal cancer (Goldenberg et al,
1981) and prostate-specific antigen in prostate cancer
(Stamey et al, 1987). A number of proteins have also been
investigated as markers in the serum of patients with me-
lanoma. Those most studied are S100B (Deichmann et al,
1999; Kra¨hn et al, 2001; Bottoni et al, 2003), LDH (Franzke
et al, 1998; Deichmann et al, 1999; Kra¨hn et al, 2001), and
melanoma inhibitory activity (Kra¨hn et al, 2001; Matsushita
et al, 2002; Faries et al, 2003). Most often, these markers
have been investigated in patients with stage IV disease. In
addition, there have been few comparisons of their pres-
ence in age- and sex-matched normal individuals. There is a
need to find serum markers that can serve as indicators in
patients with less advanced melanoma and their presence
and level must be compared with that in age- and sex-
matched controls in order to establish meaningful sensitivity
and specificity.
A number of antigens are expressed by both malignant
cells and normal tissues but in greater amounts by cancer
cells. Cancer cells can also shed some of these antigens
(Bystryn et al, 1981; Natali et al, 1982; Giacomini et al,
1984), resulting in their appearance in serum of patients
with cancer (Natali et al, 1983; Giacomini et al, 1984). We
have developed sensitive and quantitative assays to
measure serum levels for two such antigens. One is
the high-molecular-weight melanoma-associated antigen
(HMW-MAA), a membrane proteoglycan consisting of two
subunits of 280 and 440 kDa, expressed in a high propor-
tion of melanomas. Its expression correlates with poorer
clinical outcome in acral lentiginous melanoma (Wilson et al,
1981; Giacomini et al, 1984; Kageshita et al, 1993). The
other one is the cytoplasmic melanoma-associated antigen
(CYT-MAA), which is composed of four polypeptides of 94,
75, 70, and 25 kDa. It is expressed in the cytoplasm of
normal cells but to a higher degree in melanoma and other
malignant cell types. Both antigens are shed by melanoma
cells in culture. Previous studies have found both HMW-
MAA and CYT-MAA in the sera of normal individuals
and patients with melanoma (Natali et al, 1983; Giacomini
et al, 1984).
Here we report the results of a pilot study in which we
compared the measurements of CYT-MAA and HMW-MAA
in the sera of patients with different stages of melanoma
with normal age- and sex-matched controls. Furthermore,
we investigated whether the presence of either of these
antigens was associated with clinical outcome.
Abbreviations: CYT-MAA, cytoplasmic melanoma-associated
antigen; HMW-MAA, high-molecular-weight melanoma-associat-
ed antigen; mAb, monoclonal antibody; ROC, receiver operating
characteristic
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Results
Patient characteristics The study was conducted on sera
collected from 117 randomly selected patients, 68% males
and 32% females, with malignant melanoma who were en-
rolled into melanoma vaccine trials. The sera were collected
within 2 wk before the initiation of treatment. The median
age (range) was 55 (16–77) y. Thirty had resected American
Joint Committee on Cancer (AJCC) stage IIb or IIIa, 30 had
resected stage IIc, IIIb, or IIIc, 30 had resected stage IV, and
27 had measurable stage IV melanoma. Sixty-two control
sera were sex matched to the melanoma patients, and
matched in 5-y intervals by age.
Linearity and reproducibility of double-sandwich ELISA
for CYT-MAA and HMW-MAA To determine the linearity of
the standard curves, serial dilutions of a standard lot of
melanoma cell lysate known to express CYT-MAA and
HMW-MAA were assayed in triplicate on 3 d. Each assay
was quantitative, showing a linear relation between the
amount of antigen present and the read-out of the assay
(data not shown). The correlation coefficients (r) were close
to 1.00 for all assays, with r-values ranging from 0.97 to 0.99
for all curves for both antigens. The repeatability or preci-
sion with the same operator for replicate patients’ samples
(three replicates) tested on 4 d had coefficients of variation
of less than 10% (7.7% and 4.8% for CYT-MAA and HMW-
MAA, respectively). The reproducibility of the assay was
determined by repeating the baseline readings of 117 vac-
cine-treated patients on 2 different days. A regression curve
was constructed using the two readings of every patient.
The fit of the line was close to 1.00 (R2¼ 0.993). The slope
was 0.98 and the y-intercept was close to zero (0.184).
Presence and level of CYT-MAA and HMW-MAA in the
sera of patients with melanoma and controls As shown
in Fig 1 and summarized in Table I, the median serum levels
of both antigens were significantly higher in melanoma pa-
tients than in control sera. The median level of CYT-MAA
was 4.8 U in melanoma patients versus 2.6 U in controls
(po0.01), and HMW-MAA was 4.1 vs 1.2 U (p¼0.03).
To determine the serum antigen level that should be
considered elevated, the cutoff levels were calculated for
each antigen using receiver operating characteristic (ROC)
curves. The optimal level of each antigen that best sepa-
rated melanoma patients from controls based on the high-
est point attained on the ROC curve for CYT-MAA was X1.0
U (ROC curve value¼0.967), and for HMW-MAA was X1.0
U (ROC curve value¼ 0.998) (data not shown). Based on
these criteria, both antigens were found to be elevated, with
significantly higher frequency in the sera of melanoma pa-
tients than in those of controls (see Table I). CYT-MAA was
elevated in 71 (61%) of melanoma patients versus 7 (11%)
of controls (po0.01), and HMW-MAA was elevated in 34
(29%) patients versus 2 (3%) of controls (po0.01). Sera
from melanoma patients were 12.1 times more likely to be
elevated for CYT-MAA (95% CI¼5.1, 28.9) and 12.3 times
for HMW-MAA (95% CI¼2.9, 52.8) compared with controls.
Relation between the stage of disease and serum mark-
er levels As shown in Fig 2, median CYT-MAA levels were
equally high in all stages of melanoma. Although patients
with stage IV measurable disease had the highest median
serum level of 6.8 U, patients in the other three risk groups
had only slightly lower median levels ranging from 4.5 to 4.7
U. Likewise, median levels of HMW-MAA were also similar
in all stages of disease. Although the serum levels of HMW-
MAA were higher in patients with resected stage IV disease
than in the other patients, the difference did not reach the
level of statistical significance.
The frequency of patients who had elevated serum levels
for both antigens is summarized in Table II. CYT-MAA was
found to be the most frequently elevated marker regardless
of the disease stage. Sixteen (53%), 20 (67%), 19 (63%),
and 16 (59%) of the patients with resected stage IIb or IIIa,
resected stage IIc, IIIb, or IIIc, resected stage IV, and meas-
urable stage IV melanoma, respectively, had elevated lev-
els. HMW-MAA was elevated in 7 (23%), 10 (33%), 11
(37%), and 6 (22%) of the patients with resected stage IIb
or IIIa, resected stage IIc, IIIb, or IIIc, resected stage IV, and
measurable stage IV melanoma, respectively.
Effect of measuring both markers on sensitivity and
speciﬁcity of detecting a melanoma antigen in serum As
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Figure1
Serum levels (U per mL) of cytoplasmic melanoma-associated an-
tigens (CYT-MAA) and high-molecular-weight melanoma-associ-
ated antigen (HMW-MAA) in 117 patients with melanoma and 62
controls. Each point is the median of triplicate samples. All three an-
tigens were significantly higher in sera of patients with melanoma than
in controls.
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there was considerable heterogeneity of the presence in the
sera of any one melanoma antigen, we examined whether
measuring both antigens in the same serum sample could
enhance the sensitivity and specificity of the analysis. As
shown in Table III, the highest specificity of 97% was ob-
served when HMW-MAA was measured alone. The sensi-
tivity, however, was low—only 29%. Measurement of both
antigens simultaneously increased the sensitivity of detect-
ing elevated levels in melanoma patients to 74%, an in-
crease of 13% over measuring CYT-MAA alone, whereas
the specificity remained high (86%).
Relation between elevated serum antigen level and clin-
ical outcome Cox proportional hazards models were used to
test whether elevation in the level of either marker correlated
with recurrence or progression-free survival. Seventy-one out
of 117 (61%) of patients had recurrence during follow-up. The
median time to recurrence or progression for all patients was
315 d; the median time to recurrence or progression among
the 61% of the patients who had an event was 196 d.
A preliminary univariate analysis revealed statistically
significant associations for stage, age, and elevated CYT-
MAA; the results are shown in Table IV. Patients who had
elevated CYT-MAA prior to treatment had an 80% increased
risk of progression of melanoma during follow-up relative to
patients in whom CYT-MAA was undetectable (hazard ra-
tio¼1.80, 95% CI¼ [1.07, 3.03], p-value¼0.03).
For the multivariate analyses, the relationship between
CYT-MAA or HMW-MAA and recurrence or progression was
adjusted for age and stage of disease, including separate
staging for patients who had measurable stage IV disease.
The relation between CYT-MAA and recurrence or progres-
sion remained significant; patients with elevated CYT-MAA
were at 81% increased risk of recurrence or progression
relative to CYT-MAA-negative patients (hazard ratio¼ 1.81,
95% CI¼ [1.07, 3.06], p-value¼ 0.03). Interactions between
elevated marker and stage were not significant (40.10), in-
dicating that the observed adjusted relationship between
CYT-MAA or HMW-MAA and the risk of recurrence or pro-
gression did not depend on stage. Thus, CYT-MAA ap-
peared to be an independent predictor of early recurrence
or progression. The Kaplan–Meier survival estimates for
CYT-MAA are summarized in Fig 3.
Elevated HMW-MAA was not associated with early pro-
gression in either univariate or multivariate analyses. Fur-
thermore, the prognostic value of the detection of CYT-MAA
in serum of patients with melanoma was not improved by
combining the results related to the detection of HMW-
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Figure 2
Median serum levels (U per mL) of cytoplasmic melanoma-asso-
ciated antigens (’), and high-molecular-weight melanoma-asso-
ciated antigen (&) in different stages of melanoma. The levels of
both antigens were equally high in all stages of melanoma.
Table II. Relation between the stage of melanoma and detec-
tion of serum CYT-MAA and HMW-MAA
Melanoma stage
% positive (n)
CYT-MAA HMW-MAA
IIb or IIIa (n¼30) 53% (16) 23% (7)
IIc, IIIb, or IIIc (n¼ 30) 67% (20) 33% (10)
IV resected (n¼30) 63% (19) 37% (11)
IV measurable (n¼27) 59% (16) 22% (6)
All stages (n¼ 117) 61% (71) 29% (34)
Controls (n¼ 62) 11% (7) 3% (2)
CYT-MAA, cytoplasmic melanoma-associated antigens; HMW-MAA,
high-molecular-weight melanoma-associated antigen.
Table I. Median levels of CYT-MAA and HMW-MAA in serum of patients with melanoma and controls without melanoma
Antigen
Patients n (%)
(n¼117)
Controls n (%)
(n¼ 62) OR [95% CI] p-value
CYT-MAA
Median serum level 4.8 U per mL 2.6 U per mL o0.01a
% elevated 71 (61%) 7 (11%) 12.1 [5.1, 28.9] o0.01b
HMW-MAA
Median serum level 4.1 U per mL 1.2 U per mL ¼0.03a
% elevated 34 (29%) 2 (3%) 12.3 [2.9, 52.8] o0.01b
aStudent’s t test.
bw2 test.
OR, odds ratio; CYT-MAA, cytoplasmic melanoma-associated antigens; HMW-MAA, high-molecular-weight melanoma-associated antigen.
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MAA. It should be noted that no patients died prior to a
recurrence or progression event. Therefore, competing risks
does not pose a challenge in the interpretation of these
results.
Discussion
Both HMW-MAA and CYT-MAA can be present in the sera
of healthy donors as well as patients with melanoma. But
they are both expressed to a much higher degree in me-
lanoma cells. In one early study, one of us found no differ-
ence in levels between normal and patients’ sera (Natali
et al, 1982). One of the differences between the previous
study and the present one is that the dilution of serum used
in the former study was 1:50. In this study, we found that if
sera is diluted 1:1600, there is a clear difference between
normal and melanoma patient sera. Therefore, it is impor-
tant to evaluate a broad range of serum dilutions when set-
ting up assays.
Although CYT-MAA appears to be the most promising
marker in our study, to further develop and standardize an
assay for this antigen, the cutoff that we established using
ROC analysis will have to be confirmed with a second data
set with melanoma patients and control sera in future stud-
ies. Furthermore, it would be desirable to have a recom-
binant antigen to be used as a standard for assays. We
believe that that CYT-MAA may be the same as the protein
cloned and sequenced by Koths et al (1993), which is also
known as Mac-2 BP, a galactin-binding protein. This protein
has been reported to be a potent immune stimulator (Ullrich
et al, 1994) and associated with many different types of
cancer (Grassadonia et al, 2004) as well as a marker for
melanoma (Cesinaro et al, 2002). We plan to confirm that
CYT-MAA is the same as Mac-2 BP and produce the re-
combinant protein in order to confirm the usefulness of this
protein as a marker for melanoma and other malignancies in
larger prospective studies. Since the percent of patients
showing elevated levels of serum CYT-MAA in this study
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Figure3
Kaplan–Meier analysis of recurrence or progression-free survival
of patients with non-detectable cytoplasmic melanoma-associat-
ed antigens (CYT-MAA) (solid line) versus those with detectable
CYT-MAA (dotted line). Patients with CYT-MAA were significantly
more likely to recur or progress.
Table III. Sensitivity and speciﬁcity of measuring single
markers or multiple markers concurrently
Antigenic marker Sensitivity (%)a Speciﬁcity (%)b
CYT-MAA 61 89
HMW-MAA 29 97
CYT-MAA or HMW-MAA 74 86
a% of all those with disease who had a positive test result.
b% of those without the disease who had a negative test result.
CYT-MAA, cytoplasmic melanoma-associated antigens; HMW-MAA,
high-molecular-weight melanoma-associated antigen.
Table IV. Cox proportional hazards analysis of time to progression or recurrence of melanoma
Model type Pre-treatment antigen parameter Hazard ratio [95% CI] p-value
Univariate
CYT-MAAX1.0 1.80 [1.07, 3.03] 0.03
HMW-MAAX1.0 0.96 [0.57, 1.62] 0.87
CYT-MAA or HMW-MAAX1.0 1.57 [0.87, 2.82] 0.13
Stage IIc/IIIb/IIIc resected 2.45 [1.08, 5.57] 0.03
Stage IV resected 3.39 [1.56, 7.34] o0.01
Stage IV measurable 5.33 [2.45, 11.61] o0.01
Age category 1.10 [1.00, 1.20] 0.05
Gender 0.74 [0.44, 1.26] 0.27
Multivariatea
CYT-MAAX1.0 1.81 [1.07, 3.06] 0.03
HMW-MAAX1.0 0.94 [0.55, 1.59] 0.81
aModels that included stage of melanoma and patient age at baseline.
CYT-MAA, cytoplasmic melanoma-associated antigens; HMW-MAA, high-molecular-weight melanoma-associated antigen.
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was very high for all disease stages, this antigen has great
potential as a prognostic marker for melanoma.
Materials and Methods
Patients and controls This study was conducted on the sera of
117 patients with melanoma who were enrolled in clinical trials of a
polyvalent, shed antigen, melanoma vaccine. The sera were col-
lected from all patients within 2 wk before the start of treatment.
The patients were selected randomly from a group of over 500
vaccine-treated patients who had been stratified into four risk
groups based on the stage of their disease according to the 2001
AJCC staging for cutaneous melanoma (Balch et al, 2001). Within
each strata, 27–30 patients were selected using a random digit
table. The patients included 30 with resected stage IIb or IIIa, 30
with resected stage IIc, stage IIIb, or IIIc, 30 with resected stage IV
(distant metastasis) and 27 with measurable AJCC stage IV me-
lanoma. The majority of resected patients had their surgery 2–4 mo
before the start of the trials. All patients gave informed consent at
the time of their vaccine trial for their sera to be used in future
studies. All patient studies were conducted using adherence to
Helsinki guidelines.
Sera from 58 healthy blood bank donors and four non-
melanoma patients were used as controls. The non-melanoma
patients were being treated for skin rashes. These sera were fre-
quency matched to melanoma patients for sex and age (in 5 y age
groups). All sera were coded and tested without knowledge of the
patient’s clinical status. The study was approved by the New York
University School of Medicine Institutional Review Board of Re-
search Associates.
Vaccine treatment and clinical outcome All patients were treat-
ed with the same polyvalent shed antigen melanoma vaccine ad-
ministered intradermally every 2–3 wk  4 monthly  3, every 3
mo  2, and then every 6 mo for a total of 2–5 y or until disease
progression. Patients were monitored every 3 wk during the first 2
mo and then at intervals of 1–3 mo during the first year and every 3
mo thereafter. Laboratory studies (blood count and liver function
tests) were performed every 3 mo, chest X-rays every 6 mo, and
computer tomography scans of the brain, chest, and abdomen
once a year or as clinically indicated.
Monoclonal antibodies (mAb) The mAb 465.125, which recog-
nizes a repeating determinant of CYT-MAA, and the mAb TP41.2
and 763.74, which recognize distinct and spatially distant deter-
minants of HMW-MAA, were developed and characterized as de-
scribed (Natali et al, 1983; Giacomini et al, 1984). Because 465.125
recognizes a repeating epitope of CYT-MAA, it can be used in
assays for both capture and detection of the antigen. For detec-
tion, mAb 465.12 and 763.74 were biotinylated with biotinamidoca-
proate N-hydroxysuccinimide ester (Sigma, St. Louis, Missouri) as
described (Heitzmann and Richards, 1974).
Preparation of standard antigen lysate The amount of CYT-MAA
and HMW-MAA was calculated by reference to a standard curve
generated by preparing serial dilutions of a standard lot of me-
lanoma cell lysate prepared from the melanoma cell line, HT-144
(ATCC, Manassas, Virginia), which expresses both antigens. The
lysate was prepared by gently grinding on ice for 20 min, 1  108
HT-144 cells resuspended in 0.5% NP-40 in PBS with protease
inhibitors in a Tenbroeck tissue grinder. After a further 20 min in-
cubation on ice, the preparation was centrifuged for 15 min at
10,000  g. The supernatant was collected, and the protein con-
centration was determined by the BCA assay (Pierce, Rockford,
Illinois).
Assays of serum levels of CYT-MAA and HMW-MAA: The two
antigens were measured by double-sandwich ELISA. Plates (Max-
isorp, Nunc, Rochester, New York) were coated with 0.01 mg per
mL anti-CYT-MAA mAb 465.125 or anti-HMW-MAA mAb TP41.2
and incubated overnight at 41C. They were then washed 3  with
0.05% Tween/PBS and blocked for 1 h with 0.3% Tween/PBS.
Sera diluted in blocking buffer 1:1600 for CYT-MAA and 1:50 for
HMW-MAA were added and incubated overnight at 41C. These
dilutions were determined in preliminary studies as optimal for
yielding readings that were within the quantitative range of each
assay. After washing 3  as above, biotinylated anti-CYT-MAA
mAb 465.125 or anti-HMW-MAA mAb 763.74 was added and in-
cubated for an additional 2 h at 371C. The plates were washed 3 
and incubated with horseradish peroxidase–streptavidin conjugate
(Sigma) for 1 h, then washed and developed with TMB peroxidase
substrate (KPL, Gaithersburg, Maryland). Serum levels of each
antigen were calculated from the standard curve and expressed in
‘‘units’’, where 1 U equaled the amount of CYT-MAA and HMW-
MAA in 1 mg per mL of the standard cell lysate. Serum from each
patient was assayed for both antigens on the same day. All assays
were performed in triplicate, and the median value for each of the
triplicates was used for statistical analysis. A standard curve was
included on every assay plate.
Statistical analysis To determine the cutoff level of each antigen
to be considered elevated, ROC curves were constructed (Zweig
and Campbell, 1993) using readings for melanoma and control
sera. The number and percent of patients and controls above or
below the cutoff was determined. The median levels for cases and
controls were compared by Student’s t test. The frequencies of
elevated sera in melanoma patients and controls were compared
by the w2 test. Odds ratios were calculated for the odds of me-
lanoma cases being above the cutoff point for each marker relative
to the controls. Sensitivity was calculated from true positives/(true
positivesþ false negatives), and specificity from true negatives/
(true negativesþ false positives). Among the patients with me-
lanoma, Cox univariate and multivariate proportional hazards mod-
els were constructed to evaluate the association between the
presence of elevated marker and other risk factors (stage, age, and
sex) and time to recurrence or progression of melanoma. Recur-
rence or progression-free survival was calculated from the start of
vaccine treatment to the time of first evidence of recurrence or
disease progression.
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